Nadolol eye drops in glaucoma and ocular hypertension: a controlled clinical study of dose response and duration of action.

The betablocker nadolol was investigated with respect to dose-response relationship and duration of action on the basis of single-drop application in four groups of ten volunteers each. A significant dose-dependent IOP reduction could be verified between 0.3% and 2% drug concentration with increasing duration of action. The maximum IOP effect for the above concentrations was between 8 and 11.6 mmHg 3 h after drug application. The duration of action was more than 6 h for 0.3% and more than 9 h for 15 and 2% nadolol. Nadolol eye drops produced no effects on blood pressure or heart rate with either concentration and no ocular irritation.

RCT Entities:   Population Interventions Outcomes